Application No. 10/049,328 2 Docket No.: UAB-15402/22 Reply to Office Action of April 10, 2007

AMENDMENTS TO THE CLAIMS

 (Currently Amended) A method of treating spastic disorders, said method comprising administering to a subject having a spastic disorder a therapeutically effective amount of a compound consisting of gamma-aminobutyramide, or a pharmaceutically acceptable

salt thereof and independent of 4-chlorophyenyl-5-fluoro-2-hydroxyphenylmethanone.

2. (Original) A method according to claim 1, wherein said administering step

 (Original) A method according to claim 1, wherein said administering step further comprises intraventricularly delivering the compound.

4. (Canceled)

further comprises intrathecally delivering the compound.

- (Original) A method according to claim 1, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.
- (Original) A method according to claim 1, wherein said administering step further comprises delivering the compound to the subject through a spinal catheter.
- (Original) A method according to claim 1, wherein the spastic disorder is spastic hypertonia.

Application No. 10/049,328 3 Docket No.: UAB-15402/22
Reply to Office Action of April 10, 2007

8. (Original) A method according to claim 1, wherein the spastic disorder is dystonia.

9. (Original) A method according to claim 1, wherein the spasticity or spastic

disorder is caused by traumatic brain injury.

10. (Original) A method according to claim 2, wherein said intrathecal delivering

step comprises delivering the compound through a spinal catheter inserted in a substantially

cephalid spinal location.

11. (Currently Amended) A method for treating convulsions, said method comprising

administering to a subject either having convulsions or predisposed to convulsions a

therapeutically effective amount of a compound consisting of gamma-aminobutyramide, or a

pharmaceutically acceptable salt thereof and independent of 4-chlorophyenyl-5-fluoro-2-

hydroxyphenylmethanone.

12. (Original) A method according to claim 11, wherein said administering step

further comprises intrathecally delivering the compound.

13. (Original) A method according to claim 11, wherein said administering step

further comprises intraventricularly delivering the compound.

(Canceled)

Application No. 10/049,328 4 Docket No.: UAB-15402/22 Reply to Office Action of April 10, 2007

15. (Original) A method according to claim 11, wherein said administering step

further comprises delivering the compound to the subject through an implantable pump.

16. (Original) A method according to claim 11, wherein said administering step

further comprises delivering the compound to the subject through a catheter.

17. (Original) A method according to claim 12, wherein said intrathecal delivering

step comprises delivering the compound through a spinal catheter inserted in a substantially

cephalid spinal location.

18. (Currently Amended) A method for treating epilepsy, said method comprising

intraventricularly administering a therapeutically effective amount of a compound consisting of

gamma-aminobutyramide, or a pharmaceutically acceptable salt thereof and independent of 4-

chlorophyenyl-5-fluoro-2-hydroxyphenylmethanone.

19-25 (Canceled)

26. (Currently Amended) A method of treating idiopathic dystonia or torsional

dystonia, said method comprising administering to a subject having idiopathic dystonia or

torsional dystonia a therapeutically effective amount of a compound consisting of gamma-

aminobutyramide and independent of 4-chlorophyenyl-5-fluoro-2-hydroxyphenylmethanone.

27-39 (Canceled)